Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for quality of life and symptom control in irritable bowel syndrome
IRCT20200928048862N1Phase 2Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Duloxetine with Placebo (2 arms). Primary endpoints: Irritable bowel syndrome severity index score and IBS-related quality of life score. Started Oct 2018; status: completed.
02
Drugs
duloxetine
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on IRCT20200928048862N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200928048862N1.